Cardax
2800 Woodlawn Drive, Suite 129
Honolulu
Hawaii
96822
United States
Tel: 808-457-1400
Fax: 808-237-5901
Website: http://cardaxpharma.com/
Email: info@cardaxpharma.com
About Cardax
Cardax is focusing first on developing products utilizing astaxanthin, a naturally occurring compound demonstrated to reduce inflammation, at its source, without the harmful side effects of current anti-inflammatory treatments (e.g., steroids and NSAIDs).Astaxanthin use is supported by hundreds of peer-reviewed papers published in leading medical research journals. More than 40 human clinical trials supporting the safety and efficacy of astaxanthin have been conducted to date. As the broader scientific community has discovered the health benefits of astaxanthin, awareness and demand for astaxanthin has grown dramatically.
We expect astaxanthin to address underserved multi-billion dollar chronic disease markets, including areas such as osteoarthritis, cognitive decline, metabolic syndrome, dyslipidemia, diabetes, liver disease, and cardiovascular disease.
Cardax has strategic alliances with BASF, related to the proprietary, scalable, and cost-effective manufacture of nature-identical astaxanthin, and Capsugel, related to the proprietary formulation of astaxanthin for increased oral bioavailability. These strategic alliances provide near-term revenue potential from consumer health applications. Cardax may also pursue pharmaceutical applications.
Cardax management and Board have strong operational and technical expertise in healthcare product development and astaxanthin manufacturing and science.
Our patents protect compositions of matter, pharmaceutical compositions, and pharmaceutical uses of astaxanthin and related products in key disease areas.
The safety and efficacy of our product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.
LEADERSHIP:
CEO: David G. Watumull
CSO: Gilbert Rishton, PhD
CFO: John Russell
39 articles about Cardax
-
Cardax Reports Q2 2018 Results
8/13/2018
ZanthoSyn® Sales 4x Higher Than Q2 2017
-
Cardax Announces Successful Completion of Warrant Exchange Offer
7/30/2018
Company Raises $1.44 Million in Non-Dilutive Financing
-
Cardax Announces Extension of Warrant Exchange Offer to July 27, 2018
7/23/2018
Cardax, Inc. announced that it is extending to July 27, 2018, the period for its offer to exchange Warrants, together with a payment of $0.15 per share, for registered shares of the Cardax's common stock
-
Cardax Engages Industry Veteran Fred Sancilio, Ph.D., to Launch Orphan Drug Development Program
6/13/2018
Inflammation's major role in chronic orphan diseases supports program's strong potential
-
Cardax Adds Makarand Jawadekar, Ph.D., and Elona Kogan to its Board of Directors
6/1/2018
New director bring extensive pharmaceutical and business development expertise.
-
Cardax Reports Q1 2018 Results
5/9/2018
- ZanthoSyn® Sales Nearly 3-Fold Higher Than Q1 2017 - ZanthoSyn® #1 In Hawaii GNC Stores For Two Quarters In A Row - Accelerating Sales Trend In California And Nevada
-
Cardax Announces Warrant Exchange Offer
5/2/2018
Cardax, Inc. (OTCQB: CDXI) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission in connection with a one-time offer to allow holders of its $0.625 warrants expiring in February 2019 to exchange those warrants.
-
Cardax Reports 2017 Results
3/27/2018
Strong Revenue Growth in First Full Year of ZanthoSyn® Sales
-
ZanthoSyn From Cardax Now Available at 3,000+ GNC Corporate Stores in the U.S.
12/7/2017
This nation-wide availability builds on Cardax's previously announced national purchase order and mutual exclusivity agreement with GNC.
-
Cardax Hires Gilbert Shin as VP, Retail Sales and Marketing
12/7/2017
Mr. Shin will lead the Company's recently announced national rollout of ZanthoSyn to the more than 3,000 corporate stores across the U.S. owned and operated by GNC.
-
Cardax Reports Q3 2017 Results
11/15/2017
Cardax announced strong ZanthoSyn revenues of approximately $322,000 for the third quarter of 2017 - up nearly 5 times from the second quarter of 2017, as reported in the Company's Form 10-Q filed today.
-
Cardax Welcomes Cardiovascular Research Breakthrough
9/19/2017
-
Cardax Promotes David M. Watumull To COO; Partially Restores Compensation Company-Wide
9/8/2017
-
Cardax Release: Zanthosyn Going National With GNC
8/10/2017
-
Cardax Astaxanthin Compound Chosen For Important NIH Anti-Aging Research Program
6/19/2017
-
Cardax Q1 2017 Revenues Triple Vs. Prior Two Quarters Combined
5/15/2017
-
Cardax Release: Company Appoints Global Healthcare Executive As Independent Director
1/10/2017
-
Cardax Launches First Product ZanthoSyn
8/24/2016
-
Cardax Enters Into Equity Purchase Agreement For Financing Of Up To $5 Million
7/18/2016